Loading...
•
Dec 31, 2022
MannKind Q4 2022 Earnings Report
MannKind reported strong Q4 2022 results, marked by revenue growth and pipeline advancement.
Key Takeaways
MannKind Corporation reported a total revenue of $36.059 million for Q4 2022, a 188% increase compared to Q4 2021. The growth was driven by increased Afrezza net revenue, V-Go acquisition, higher collaborations and services revenue, and royalties from Tyvaso DPI. The company is focusing on advancing its product pipeline, including the INHALE-1 Phase 3 trial for Afrezza in pediatrics and an adaptive Phase 2/3 study for inhaled clofazimine.
Total revenues for Q4 2022 reached $36.059 million, reflecting a 188% increase compared to Q4 2021.
Commercial Products Net Revenue for Q4 2022 was $17 million, a 54% increase compared to Q4 2021.
Royalties from Tyvaso DPI for Q4 2022 were $9 million.
Cash and cash equivalents and investments totaled $173 million as of December 31, 2022.
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...